New Gift Fuels Macular Dystrophy Research at UC San Diego, Boosting Hope for IRD Community
The inherited retinal disease (IRD) community often looks to advancements in research for hope and potential treatments. A significant development in this regard comes from UC San Diego Health, where a major gift has been received to advance studies into macular dystrophy. This funding is particularly relevant to many within the IRD community, as macular dystrophies represent a group of inherited genetic eye disorders that cause progressive damage to the macula, the central part of the retina responsible for sharp, detailed vision.
According to Ophthalmology Times Europe, the Viterbi Family Department of Ophthalmology and Shiley Eye Institute, both part of UC San Diego Health, have received a substantial gift from the Nixon Visions Foundation. This funding is specifically designated to launch the Nixon Visions Foundation Macular Dystrophy-PRPH2 Research Fund. The fund will focus on studying the PRPH2 gene and related mutations, which are linked to macular dystrophy. Additionally, the gift aims to upgrade stem cell technologies, with the long-term goal of developing a proven therapeutic remedy.
Macular dystrophies are distinct from age-related macular degeneration, typically manifesting in children and young adults due to specific gene mutations. While these conditions lead to central vision loss, peripheral vision usually remains intact. Common forms include Stargardt disease, Best vitelliform macular dystrophy, and X-linked retinoschisis. The PRPH2 gene, a focus of this new research, is known to be involved in some cases of vitelliform macular dystrophy, a genetic eye disorder that can cause worsening vision loss.
For patients and families affected by inherited macular dystrophies, this investment in research at UC San Diego Health offers renewed hope. Understanding the genetic underpinnings of these conditions, such as the PRPH2 gene, is a crucial step towards developing targeted treatments and potential cures. The enhancement of stem cell research capabilities could pave the way for innovative therapies that could one day restore or preserve vision for those living with these challenging diseases. UC San Diego Chancellor Pradeep Khosla noted that macular dystrophy is a difficult disease, but stated that UC San Diego Health possesses the expertise to discover new treatments.
This dedicated funding underscores a commitment to accelerating efforts that could significantly impact individuals with inherited eye diseases, improving lives for generations to come. The research, supported by the Nixon Visions Foundation, aims to make a tremendous difference in the field of inherited retinal diseases.